ATYR - NASDAQ
aTyr Pharma, Inc.
$0.55
-4.9%aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
At a Glance
Live SnapshotaTyr Pharma, Inc. Management Team
Ms. Jill M. Broadfoot CPA
Chief Financial Officer
Compensation
$585,723
Ms. Ashlee Dunston
Director of Investor Relations & Corporate Communications
Ms. Nancy E. Denyes Krueger J.D.
General Counsel & Corporate Secretary
Compensation
$568,865
Ms. Dalia R. Rayes M.B.A.
Head of Commercial, Global Efzofitimod Franchise
Dr. Sanjay S. Shukla M.D., M.S.
President, Chief Executive Officer & Director
Compensation
$838,762
Mr. Peter Villiger
Vice President of Corporate Development
Ms. Danielle Campbell
Vice President of Human Resource
Dr. Leslie Nangle Ph.D.
Vice President of Research
Dr. Jayant Aphale MBA, Ph.D.
Vice President of Technical Operations
aTyr Pharma, Inc. Insider Positioning
During the last 12 months, insiders have purchased $961K and sold $6K worth of ATYR shares, resulting in $955K of net buying activity.
3 Months
100.0K
49.63K
0
0.00
+50K
+$50K
3-6 Months
0
0.00
6.4K
6.27K
-6K
-$6K
6-9 Months
1.0M
911.80K
0
0.00
+912K
+$912K
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
Schimmel Paul
Director
$961K
Top Sellers
Shukla Sanjay
Director, Officer: President And Ceo
$4K
Broadfoot Jill Marie
Officer: Chief Financial Officer
$2K
Denyes Nancy
Officer: General Counsel
$1K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $955K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Recent Trend (3 Months)
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
Insider Participation
3 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Sustained buying momentum: Consistent net buying over multiple quarters suggests insiders maintain conviction in the company's prospects. This is particularly meaningful if buying continued through market volatility.
SEC Filings
ATYR - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | March 26, 2026 | March 26, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | March 19, 2025 | March 19, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 05, 2024 | May 22, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | March 29, 2023 | May 17, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | March 22, 2022 | April 26, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | March 24, 2021 | April 28, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 02, 2020 | May 06, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | March 28, 2019 | May 08, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 03, 2018 | May 15, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | March 30, 2017 | May 09, 2017 | 2017 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.